Established life sciences companies, including medical device, diagnostics, biological tools and services companies, look to us for help with their exit strategies. We have worked with thousands of companies for successful sales, initial public offerings or strategic collaborations. In the past five years alone, we have completed hundreds of life sciences public offerings and M&A transactions totaling over $84 billion, including transactions requiring highly complex M&A structures. He has also advised hundreds of life sciences companies on building strategic commercial partnerships.
Experience advising companies on both the buy and sell sides of the negotiating table includes small “tuck-in” acquisitions, strategic mergers and business combinations, complex cross-border transactions, spin-offs, and tangible transactions. Includes almost all types of M&A transactions, including Acquisition of intangible assets. His M&A work at the firm has earned him numerous awards and recognition, consistently ranking him among the top M&A advisors across all industries in the US by sources such as Refinitiv, Bloomberg and Mergermarket.
For companies considering an IPO as an exit strategy, an IPO portends the realization of a client’s business vision with a comprehensive process honed in hundreds of transactions. A successful IPO requires a dedicated team to manage and prepare all aspects of the offering, leveraging connections throughout the company, including the highest levels of the U.S. Securities and Exchange Commission and local exchanges throughout the trading period. I know that From competitor actions to government shutdowns to changing economic and market conditions, unforeseen hurdles must be addressed.
Many chose to go public because the firm’s attorneys nurtured promising start-ups through the business life cycle. The evolution of clients from privately held to public companies is Wilson one of his reasons.
Sonsini has successfully built a respected, top-ranked public company practice. With the firm, he has over 300 publicly traded clients and is a highly regarded advisor to companies, boards and board committees.